Table 3.
Treatment‐Related AEs
| AEs | Pembrolizumab (n = 35), No. (%) | Pembrolizumab + Acalabrutinib (n = 40), No. (%) |
|---|---|---|
| Any AEs related to acalabrutinib | ||
| Grade 1/2 | — | 11 (27.5) |
| Grade 3/4 | — | 8 (20.0) |
| Most frequent AEs related to acalabrutinib a | ||
| Fatigue | — | 6 (15.0) |
| Nausea | — | 2 (5.0) |
| Vomiting | — | 2 (5.0) |
| Anemia | — | 2 (5.0) |
| Decreased appetite | — | 2 (5.0) |
| Diarrhea | — | 2 (5.0) |
| Headache | — | 2 (5.0) |
| Decreased platelet count | — | 2 (5.0) |
| Any AEs related to pembrolizumab | ||
| Grade 1/2 | 23 (65.7) | 11 (27.5) |
| Grade 3/4 | 7 (20) | 9 (22.5) |
| Grade 5 | 0 | 1 (2.5) |
| Most frequent AEs related to pembrolizumab a | ||
| Fatigue | 12 (34.3) | 6 (15.0) |
| Decreased appetite | 6 (17.1) | 2 (5.0) |
| Diarrhea | 3 (8.6) | 5 (12.5) |
| Hypothyroidism | 6 (17.1) | 1 (2.5) |
| Rash, maculopapular | 4 (11.4) | 3 (7.5) |
| ALT increase | 2 (5.7) | 5 (12.5) |
| Rash | 4 (11.4) | 3 (7.5) |
| AST increase | 1 (2.9) | 5 (12.5) |
| Nausea | 4 (11.4) | 2 (5.0) |
| Pruritus | 3 (8.6) | 2 (5.0) |
| Vomiting | 3 (8.6) | 2 (5.0) |
| Anemia | 2 (5.7) | 2 (5.0) |
| Dry skin | 2 (5.7) | 2 (5.0) |
| Peripheral edema | 1 (2.9) | 3 (7.5) |
| Abdominal pain | 1 (2.9) | 2 (5.0) |
| Arthralgia | 2 (5.7) | 1 (2.5) |
| Cough | 0 | 3 (7.5) |
| Dry mouth | 2 (5.7) | 1 (2.5) |
| Dyspnea | 0 | 3 (7.5) |
| Infusion‐related reaction | 2 (5.7) | 1 (2.5) |
| Pneumonia | 2 (5.7) | 1 (2.5) |
| Pyrexia | 2 (5.7) | 1 (2.5) |
| Blood alkaline phosphatase increase | 0 | 2 (5.0) |
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
a
All grades; 2 or more patients.